Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasIndolent LymphomasDiseaseAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentSubgroupICD10C82.-C82.7C82.9C83.1C83.3C83.7C91.0-C91.1-MeSHLymphoma, Mantle-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)ChemotherapyChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabNo. Substances1 RadiotherapySupportive therapySupportive substanceDimetindenParacetamolPrednisoloneSupportive substanceDimetindenParacetamolPrednisoloneSupportive substanceDimetindenParacetamolPrednisoloneSupportive substanceDimetindenParacetamolPrednisoloneNo. Substances3Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionRisks only studiesPublicationAuthorDavies ADiseaseOriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieProtocols in Revision 1 protocol foundProtocols under revision.Rituximab 1400, single dose subcutaneous (PID310 V2.0)
